

Parkwalk Opportunities EIS Fund

An early stage investment fund providing tax benefits under the Enterprise Investment Scheme




UK's most active investor in university spinouts



Award-winning 15 year track record



Strong Performance:
£150m+ cash back to investors to date



EIS Fund at a glance:

Sector:
Knowledge
Intensive university spinouts

Investment stage:
Series A-C

Portfolio size:
8 individual companies

Close date:
Evergreen

Target deployment:
12-18 months from initial subscription

Min investment:
£25,000

Do not invest unless you are prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Please refer to the Risk Summary document for further information.

About Parkwalk

Parkwalk is the largest growth EIS fund manager, backing world-changing technologies from the UK's leading universities and research institutions. With circa £500m of assets under management, it has invested in over 180 companies.

We are the UK's most active investor in university spinouts. We combine investment expertise, expansive networks, and extensive experience in turning pioneering research into successful, impactful companies.

At Parkwalk, we understand the transformative potential of deep tech innovations born from the UK's world-class university research. We have over 15 years' experience nurturing groundbreaking ideas into successful, impactful businesses, and we know that converting pioneering research into commercial innovations takes unwavering commitment and support.

That's why we partner with the boldest, most visionary university spinouts, providing the funding, expertise, and networks they need to thrive.

As a leading EIS fund manager, we offer investors tax-efficient opportunities to support these groundbreaking ventures. Our approach drives economic growth and improves lives worldwide. It aims to generate significant returns for our investors, UK plc, and broader society.

100+

Portfolio companies

£500m+

AUM

£50m+

Invested annually on average
over the last 6 years

60+ exits

to date

// Parkwalk is the UK's most active investor in university spinouts

Beaumont 'Equity investment into spinouts' report 2024

Data as at October 2024

Key Risks:

EIS investments involve a high degree of risk and are not suitable for all investors. Please see the risk warnings section in this summary, they must be read in conjunction with the Fund Information Memorandum. Investors could lose part or all of their capital invested.

Investment Strategy

4 out of 10 top rated universities in the world are British


QS World Rankings 2024

We believe the distinct asset class of university spinouts has the ability not only to generate attractive investment returns but also positive returns for broader society.

- Founded in 2009, Parkwalk invest in world-class university spinouts in 'hard science' and deep-tech, commercialising scientific discoveries backed by intellectual property.
- We have unparalleled deal flow in this sector, including managing early-stage funds in partnership with the Tech Transfer Offices of the universities of Cambridge, Oxford, Bristol and Imperial College
- The 180+ companies we have invested in to date are developing groundbreaking university research into successful businesses, spanning sectors including life sciences, AI, quantum computing, advanced materials, genomics, cleantech, future of mobility, medtech, and big data.


Diversified Portfolio

Investors' funds are allocated across a portfolio of eight companies. Risk is mitigated via diversification across a spread of technology sectors and investment maturities.



Series A
Series B
Series C
AIM Listed

Data as at October 2024



AI Big Data & Software
CleanTech
Digital Health & MedTech
Digital Media
Future Mobility
Hardware
Life Sciences
Materials
AG-Tech
Quantum Computing

Data as at October 2024

MEDTECH

Brainomix

Oxford



Pioneering AI for faster and more effective access to stroke treatment

Brainomix is a University of Oxford spinout using AI platforms to transform the diagnosis and treatment of conditions such as stroke and cancer. The company's first product, the Brainomix 360 Stroke platform, reduces the time taken to interpret brain scans, allowing for faster treatment decisions and much reduced timescales for patients to access potentially life-saving procedures.

The platform has been widely adopted across multiple healthcare systems worldwide, has received FDA approval and is also being adopted across multiple NHS trusts. Further platforms, one for the assessment of interstitial lung disease and another for solid tumour assessment, are currently in clinical trials.

● brainomix.com

HARDWARE

Cambridge GAN Devices

Cambridge



Energy-efficient GaN-based power devices to make greener electronics possible

Our dependence on electronic devices comes at a high environmental cost, particularly in the energy they consume during operation. This energy consumption contributes significantly to our carbon footprint and the depletion of natural resources. Cambridge GaN Devices (CGD), a spin-out of the University of Cambridge, is addressing this issue with their innovative technology.


Gallium nitride (GaN) transistors have long been recognised as more energy efficient than their silicon equivalents, but their implementation has been challenging. However, CGD's product, ICeGaN(TM), has overcome these challenges.

● camgandevices.com

AI

Cytora

Cambridge



The future of commercial insurance, powered by Generative AI

Cytora, a spinout from the University of Cambridge, is transforming underwriting for commercial insurance. The company's software platform uses generative AI, enabling insurers to accelerate configurability, scalability and performance across all lines of business.

Built for commercial and specialty insurance, Cytora's AI-powered platform enables insurers to digitize and streamline their core workflows driving improved growth, profitability and service. Its technology can detect factual, real world events from unstructured text, and the platform is uniquely configured for each insurer accelerating competitive differentiation.

● cytora.com

AI

Mind Foundry

Oxford



A platform for responsible AI

Mind Foundry is a University of Oxford company that combines innovation, research, and usability to empower teams with AI for high-stakes applications. The company's software is used across high risk and complex industries such as Defence & National Security, Infrastructure, and Insurance.

Mind Foundry aims to create a future where humans and AI work together to solve the world's most important problems.

● mindfoundry.ai

AGRI-TECH

MOA Technology

Oxford



Cultivating a revolution in herbicidal discovery

MOA Technology is a plant genetics company, spun out of the University of Oxford. Drawing on pioneering research, the company has reinvented the way herbicides are created with a biology-led approach.

The company has a team of world-class scientists researching and developing new modes of action - both synthetic and biological - to provide farmers with a whole range of better options to help protect their harvests against weeds.

MOA has several commercial partnerships in place including with Nufarm, a global agricultural innovator.

● moa-technology.com

FUTURE MOBILITY

OXA

Oxford



Changing the way the world moves

Oxa is a University of Oxford spinout, and a global leader in self-driving software and services that unlock the power of autonomy.

Oxbotica's operating system Universal Autonomy™ allows any vehicle, of any size, in any place to operate autonomously, safely and sustainably. The company has several partnerships including with the Ocado Group, where autonomous goods delivery will fulfil customer orders. Other commercial deployments include Oxa Driver in collaboration with Beep, Inc, with driverless AV shuttles servicing Rossmore Walnut Creek, a 55+ active senior community in the US.

● oxa.tech

How to invest

After reading the Information Memorandum and you have consulted your financial adviser, please complete the relevant Application Form and return either:



Scanned copy to:
investor.relations@parkwalkadvisors.com



By Post to: **Apex Unitas Ltd**
140 Aldersgate Street, London EC1A 4HY

If you have any questions regarding applications please contact the Parkwalk team on **020 7759 2285**.

Fees

Parkwalk's fee structure is competitive. In addition, Parkwalk generally avoids charging monitoring or other hidden fees to portfolio companies.

Initial Fee	3.0%
Annual Management Fee	1.5% (paid in cash for 2.5 years then accrued) VAT applicable
Performance Fee	20% only after investors have received back £1 per £1 invested, net of adviser fees. Performance fee payable on a portfolio basis
Third Party Custodian Fees	0.20% dealing charge, 0.25% admin charge, taken for 5 years
Total % available for tax relief	Target of 91% of initial subscription (excluding any adviser fees)

Awards

Parkwalk has won 20 awards, including from: Investment Week, the EIS Association and the Growth Investor Awards. Most recently, the team were awarded 'Best EIS Investment Manager' for two consecutive years at the Growth Investor Awards in 2023 and 2022.



Risk Warning:

This financial promotion was approved on DATE and is issued by Parkwalk Advisors Limited ("Parkwalk") which is authorised and regulated by the Financial Conduct Authority with firm reference number 502237. Investments referred to in this publication are not suitable for all investors.

Interested parties are strongly recommended to seek specialist financial and tax advice before investing in any product. Capital is at risk and investors may not get back the full amount invested. Tax treatment depends on the individual circumstances of each investor and may be subject to change.

Registered address: 3 Pancras Square, King's Cross, London, N1C 4AG

Past performance is not a reliable indicator of future results, and the value of investments may go down as well as up. Projections and forecasts are also not a reliable indicator of future performance. Investments in small and unquoted companies carry a higher risk than many other forms of investment. Any investment in a Parkwalk product must only be made on the basis of the terms of the full Information Memorandum.

Parkwalk is not able to provide advice as to the suitability of investing in any product.



If you would like to discuss the fund please contact our sales team on
sales@parkwalkadvisors.com or **020 7759 2285**

Find out more **parkwalkadvisors.com**